Achieving operational tolerance in transplantation: How can lessons from the clinic inform research directions?

Transplant International

Volumn 26, Issue 6, 2013, Pages 576-589

  Chandrasekharan, Deepak ^a   Issa, Fadi ^a   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cellular therapy; clinical trials; immune regulation; regulatory T cell; tolerance; transplantation

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ATACICEPT; BASILIXIMAB; BELATACEPT; BELIMUMAB; BORTEZOMIB; CYCLOSPORIN; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; INDUCIBLE NITRIC OXIDE SYNTHASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROSTAGLANDIN E2; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; SUPPRESSOR OF CYTOKINE SIGNALING 1; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTING CELL; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CD4 CD8 RATIO; CELL PROLIFERATION; CELL THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; DRUG DOSE REGIMEN; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MEMORY T LYMPHOCYTE; MICROARRAY ANALYSIS; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PANCREAS TRANSPLANTATION; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RENAL GRAFT DYSFUNCTION; REVIEW; TRANSPLANTATION;

BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; CALCINEURIN; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 84878014212     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12081     Document Type: Review

References (120)

1. Karam V, Castaing D, Danet C, et al,. Longitudinal prospective evaluation of quality of life in adult patients before and one year after liver transplantation. Liver Transpl 2003; 9: 703.
2. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC,. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77: 769.
3. US Organ Procurement and Transplantation Network. Scientific Registry of Transplant Recipients: Annual Data Report 2011. Accessed 10 January 2013. Available from: http://srtr.transplant.hrsa.gov/annual-reports/2011/Default.aspx
4. NHS Blood and Transplant. Organ Donation-Centre-specific Reports 2011. Accessed 10 January 2013. Available from: http://www.organdonation.nhs.uk/ statistics/centre-specific-reports/.
5. Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 (Suppl. 3): S1.
6. Institute of Health and Clinical Excellence N. TA85 NICE Guideline: Renal transplantation-Immunosuppressive regimens. 2004.
7. Boudjema K, Camus C, Saliba F, et al,. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011; 11: 965.
8. Knechtle SJ,. Guidance for liver transplant immunosuppression. Am J Transplant 2011; 11: 886.
9. Sanchez-Fueyo A,. Identification of tolerant recipients following liver transplantation. Int Immunopharmacol 2010; 10: 1501.
10. Billingham R, Brent L, Medawar P,. 'Actively acquired tolerance' of foreign cells. Nature 1953; 172: 603.
11. Hasek M, Hraba T,. Immunological effects of experimental embryonal parabiosis. Nature 1955; 175: 764.
12. Owen R,. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400.
13. West LJ, Pollock-Barziv SM, Dipchand AI, et al,. ABO-incompatible heart transplantation in infants. N Engl J Med 2001; 344: 793.
14. Wood KJ, Goto R,. Mechanisms of rejection: current perspectives. Transplantation 2012; 93: 1.
15. Waldmann H, Cobbold S,. Exploiting tolerance processes in transplantation. Science 2004; 305: 209.
16. Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA,. The immune tolerance network at 10 years: tolerance research at the bedside. Nat Rev Immunol 2010; 10: 797.
17. Newell KA, Asare A, Kirk AD, et al,. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836.
18. Sagoo P, Perucha E, Sawitzki B, et al,. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848.
19. Ashton-Chess J, Giral M, Brouard S, Soulillou JP,. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation 2007; 84: 1215.
20. Orlando G, Soker S, Wood K,. Operational tolerance after liver transplantation. J Hepatol 2009; 50: 1247.
21. Orlando G, Hematti P, Stratta RJ, et al,. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg 2010; 252: 915.
22. Mazariegos GV,. Immunosuppression withdrawal after liver transplantation: what are the next steps? Transplantation 2011; 91: 697.
23. Gao Z, McAlister VC, Williams GM,. Repopulation of liver endothelium by bone-marrow-derived cells. Lancet 2001; 357: 932.
24. Svendsen UG, Aggestrup S, Heilmann C, et al,. Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. Eur Respir J 1995; 8: 334.
25. Comerci GD Jr, Williams TM, Kellie S,. Immune tolerance after total lymphoid irradiation for heart transplantation: immunosuppressant-free survival for 8 years. J Heart Lung Transplant 2009; 28: 743.
26. Starzl TE,. The "privileged" liver and hepatic tolerogenicity. Liver Transpl 2001; 7: 918.
27. Aini W, Miyagawa-Hayashino A, Ozeki M, et al,. Frequent hepatocyte chimerism in long-term human liver allografts independent of graft outcome. Transpl Immunol 2012; doi: 10.1016/j.trim.2012.12.002.
28. Levitsky J,. Operational tolerance: past lessons and future prospects. Liver Transpl 2011; 17: 222.
29. Feng S, Ekong UD, Lobritto SJ, et al,. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283.
30. Lerut J, Sanchez-Fueyo A,. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6: 1774.
31. Ohe H, Waki K, Yoshitomi M, et al,. Factors affecting operational tolerance after pediatric living-donor liver transplantation: impact of early post-transplant events and HLA match. Transpl Int 2012; 25: 97.
32. Waki K, Sugawara Y, Mizuta K, et al,. Predicting operational tolerance in pediatric living-donor liver transplantation by absence of HLA antibodies. Transplantation 2013; 95: 177.
33. Starzl TE, Murase N, Abu-Elmagd K, et al,. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502.
34. Pearl JP, Parris J, Hale DA, et al,. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465.
35. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL,. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114: 954.
36. Sellers MT, Deierhoi MH, Curtis JJ, et al,. Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up. Transplantation 2001; 71: 1681.
37. Light J, Salomon DR, Diethelm AG, et al,. Bone marrow transfusions in cadaver renal allografts: pilot trials with concurrent controls. Clin Transplant 2002; 16: 317.
38. Buhler LH, Spitzer TR, Sykes M, et al,. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405.
39. Kawai T, Cosimi AB, Spitzer TR, et al,. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353.
40. Scandling JD, Busque S, Dejbakhsh-Jones S, et al,. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362.
41. Andreola G, Chittenden M, Shaffer J, et al,. Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant 2011; 11: 1236.
42. Wu Z, Bensinger SJ, Zhang J, et al,. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 87.
43. Adams AB, Williams MA, Jones TR, et al,. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887.
44. Griesemer AD, Sorenson EC, Hardy MA,. The role of the thymus in tolerance. Transplantation 2010; 90: 465.
45. Leventhal J, Abecassis M, Miller J, et al,. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4: 124ra28.
46. Turka L, Bluestone J, Waldmann H, Sykes M,. A step closer to effective transplant tolerance? Nat Med; 18: 664.
47. Leventhal J, Abecassis M, Miller J, et al,. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation 2013; 95: 169.
48. Brouard S, Pallier A, Renaudin K, et al,. The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases. Am J Transplant 2012; 12: 3296.
49. Hutchinson JA, Riquelme P, Geissler EK,. Human regulatory macrophages as a cell-based medicinal product. Curr Opin Organ Transplant 2012; 17: 48.
50. Hutchinson JA, Riquelme P, Brem-Exner BG, et al,. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008; 21: 728.
51. Hutchinson JA, Brem-Exner BG, Riquelme P, et al,. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008; 21: 742.
52. Hutchinson JA, Riquelme P, Sawitzki B, et al,. Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 2011; 187: 2072.
53. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69: 89.
54. McCaughan JA, McKnight AJ, Courtney AE, Maxwell AP,. Epigenetics: time to translate into transplantation. Transplantation 2012; 94: 1.
55. Anglicheau D, Muthukumar T, Suthanthiran M,. MicroRNAs: small RNAs with big effects. Transplantation 2010; 90: 105.
56. Londono MC, Danger R, Giral M, Soulillou JP, Sanchez-Fueyo A, Brouard S,. A need for biomarkers of operational tolerance in liver and kidney transplantation. Am J Transplant 2012; 12: 1370.
57. Roedder S, Gao X, Sarwal MM,. The pits and pearls in translating operational tolerance biomarkers into clinical practice. Curr Opin Organ Transplant 2012; 17: 655.
58. Brouard S, Mansfield E, Braud C, et al,. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448.
59. Li L, Wozniak LJ, Rodder S, et al,. A common peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver transplantation. Am J Transplant 2012; 12: 1218.
60. Moraes-Vieira PM, Takenaka MC, Silva HM, et al,. GATA3 and a dominant regulatory gene expression profile discriminate operational tolerance in human transplantation. Clin Immunol 2012; 142: 117.
61. Lozano JJ, Pallier A, Martinez-Llordella M, et al,. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant 2011; 11: 1916.
62. Pons JA, Revilla-Nuin B, Baroja-Mazo A, et al,. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008; 86: 1370.
63. Koshiba T, Li Y, Takemura M, et al,. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007; 17: 94.
64. Li Y, Koshiba T, Yoshizawa A, et al,. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118.
65. Li XC,. The significance of non-T-cell pathways in graft rejection: implications for transplant tolerance. Transplantation 2010; 90: 1043.
66. Braudeau C, Ashton-Chess J, Giral M, et al,. Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation 2008; 86: 130.
67. Heidt S, San Segundo D, Shankar S, et al,. Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation. Transplantation 2011; 92: 1.
68. Cobbold SP, Adams E, Waldmann H,. Biomarkers of transplantation tolerance: more hopeful than helpful? Front Immunol 2011; 2: 9.
69. Braza F, Soulillou JP, Brouard S,. Gene expression signature in transplantation tolerance. Clin Chim Acta 2012; 413: 1414.
70. Becker LE, De Oliveira Biazotto F, Conrad H, et al,. Cellular infiltrates and NFkappaB subunit c-Rel signaling in kidney allografts of patients with clinical operational tolerance. Transplantation 2012; 94: 729.
71. Banff Working Group on Liver Allograft P. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012; 18: 1154.
72. Wood KJ, Bushell A, Hester J,. Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417.
73. Dons EM, Raimondi G, Cooper DK, Thomson AW,. Non-human primate regulatory T cells: current biology and implications for transplantation. Transplantation 2010; 90: 811.
74. Danger R, Pallier A, Giral M, et al,. Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. J Am Soc Nephrol 2012; 23: 597.
75. Bohne F, Martinez-Llordella M, Lozano JJ, et al,. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012; 122: 368.
76. Gandolfo MT, Jang HR, Bagnasco SM, et al,. Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int 2009; 76: 717.
77. Wood KJ, Regulatory T,. cells in transplantation. Transplant Proc 2011; 43: 2135.
78. Rubtsov YP, Rasmussen JP, Chi EY, et al,. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008; 28: 546.
79. Andersson J, Tran DQ, Pesu M, et al,. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 2008; 205: 1975.
80. Cobbold SP, Adams E, Farquhar CA, et al,. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci USA 2009; 106: 12055.
81. Groux H, Bigler M, de Vries JE, Roncarolo MG,. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996; 184: 19.
82. Liu Z, Tugulea S, Cortesini R, Lederman S, Suciu-Foca N,. Inhibition of CD40 signaling pathway in antigen presenting cells by T suppressor cells. Hum Immunol 1999; 60: 568.
83. Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L,. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 2000; 6: 782.
84. Cai J, Lee J, Jankowska-Gan E, et al,. Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med 2004; 199: 1017.
85. Dugast AS, Haudebourg T, Coulon F, et al,. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180: 7898.
86. English K, French A, Wood KJ,. Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 2010; 7: 431.
87. Fleming BD, Mosser DM,. Regulatory macrophages: setting the threshold for therapy. Eur J Immunol 2011; 41: 2498.
88. Page EK, Dar WA, Knechtle SJ,. Tolerogenic therapies in transplantation. Front Immunol 2012; 3: 198.
89. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al,. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91: 672.
90. Sykes M,. Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials. Transplantation 2009; 87: 309.
91. Jankowski RA, Ildstad ST,. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans. Hum Immunol 1997; 52: 155.
92. Sachs DH, Sykes M, Kawai T, Cosimi AB,. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol 2011; 23: 165.
93. Scandling JD, Busque S, Dejbakhsh-Jones S, et al,. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012; 12: 1133.
94. Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K,. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010; 90: 1321.
95. Issa F, Chandrasekharan D, Wood KJ,. Regulatory T cells as modulators of chronic allograft dysfunction. Curr Opin Immunol 2011; 23: 648.
96. Wieckiewicz J, Goto R, Wood KJ,. T regulatory cells and the control of alloimmunity: from characterisation to clinical application. Curr Opin Immunol 2010; 22: 662.
97. Nadig SN, Wieckiewicz J, Wu DC, et al,. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809.
98. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL,. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401.
99. Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA,. Expansion of functional endogenous antigen-specific CD4+ CD25+ regulatory T cells from nonobese diabetic mice. J Immunol 2005; 175: 3053.
100. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI,. In vitro-expanded donor alloantigen-specific CD4+ CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007; 109: 827.
101. Brusko TM, Koya RC, Zhu S, et al,. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One 2010; 5: e11726.
102. Brunstein CG, Miller JS, Cao Q, et al,. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061.
103. Edinger M, Hoffmann P,. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol 2011; 23: 679.
104. Di Ianni M, Falzetti F, Carotti A, et al,. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921.
105. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW,. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018.
106. Aggarwal S, Pittenger MF,. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815.
107. Aksu AE, Horibe E, Sacks J, et al,. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol 2008; 127: 348.
108. Le Blanc K, Frassoni F, Ball L, et al,. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579.
109. Ankrum J, Karp JM,. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med 2010; 16: 203.
110. Leslie M. Immunology,. Regulatory T cells get their chance to shine. Science 2011; 332: 1020.
111. Issa F, Wood KJ,. Translating tolerogenic therapies to the clinic-where do we stand? Front Immunol 2012; 3: 254.
112. McMurchy AN, Bushell A, Levings MK, Wood KJ,. Moving to tolerance: clinical application of T regulatory cells. Semin Immunol 2011; 23: 304.
113. Braud C, Baeten D, Giral M, et al,. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: part I. Blood gene expression statistical analysis. J Cell Biochem 2008; 103: 1681.
114. Sivozhelezov V, Braud C, Giacomelli L, et al,. Immunosuppressive drug-free operational immune tolerance in human kidney transplants recipients. Part II. Non-statistical gene microarray analysis. J Cell Biochem 2008; 103: 1693.
115. Brouard S, Le Bars A, Dufay A, et al,. Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int 2011; 24: 536.
116. Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI,. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation 2012; 93: 1173.
117. Danger R, Thervet E, Grisoni ML, et al,. PARVG gene polymorphism and operational renal allograft tolerance. Transplant Proc 2012; 44: 2845.
118. Martinez-Llordella M, Puig-Pey I, Orlando G, et al,. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309.
119. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al,. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845.
120. Castellaneta A, Mazariegos GV, Nayyar N, Zeevi A, Thomson AW,. HLA-G level on monocytoid dendritic cells correlates with regulatory T-cell Foxp3 expression in liver transplant tolerance. Transplantation 2011; 91: 1132.